With FDA re­view of its gene ther­a­py un­der­way, Fer­ring's $570M spin­out de­liv­ers in PhI­II blad­der can­cer read­out

Fer­Gene was born ready. By the time Fer­ring spun out the biotech with a gene ther­a­py li­censed from FKD Ther­a­pies Oy and $400 mil­lion in cash from Black­stone, they had se­cured a pri­or­i­ty re­view on their BLA and point­ed to an im­mi­nent date for the piv­otal Phase III read­out in blad­der can­cer.

The date came yes­ter­day, and Fer­Gene said its ex­per­i­men­tal drug did not dis­ap­point.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER